Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: Effect of sex and the LIPC promoter variant

Diabetes Care

Volumn 26, Issue 2, 2003, Pages 427-432

  Berk Planken, Ingrid I L ^a   Hoogerbrugge, Nicoline ^a,b   Stolk, Ronald P ^c   Bootsma, Aart H ^a   Jansen, Hans ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; ENZYME INHIBITOR; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ALLELISM; ARTICLE; CAUCASIAN; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME ACTIVITY; ETHNIC DIFFERENCE; FEMALE; GENE; GENETIC POLYMORPHISM; HUMAN; LIPC GENE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROMOTER REGION; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; ALLELE; DRUG ANTAGONISM; ENZYMOLOGY; ETHNOLOGY; GENETIC VARIABILITY; GENETICS; HETEROZYGOTE; HYPERLIPIDEMIA; LIVER; METABOLISM; MIDDLE AGED; SEXUAL DEVELOPMENT;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ALLELES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPTANOIC ACIDS; HETEROZYGOTE; HUMANS; HYPERLIPIDEMIAS; LIPASE; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PYRROLES; SEX CHARACTERISTICS; VARIATION (GENETICS);

EID: 0042309721     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.2.427     Document Type: Article

References (41)

1. Santamarina-Fojo S, Haudenschild C, Amar M: The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 9:211-219, 1989
2. Jansen H, Hülsmann WC: Heparin-releasable (liver) lipase(s) may play a role in the uptake of cholesterol by steroid-secreting tissues. Trends Biochem Sci 5:265-268, 1980
3. Kadowaki H, Patton GM, Robins SJ: Metabolism of high density lipoprotein lipids by the rat liver: evidence for participation of hepatic lipase in the uptake of cholesteryl esters. J Lipid Res 33:1689-1698, 1992
4. Applebaum-Bowden D, Haffner SM, Wahl PW, Hoover JJ, Warnick GR, Albers JJ, Hazzard WR: Postheparin plasma triglyceride lipases: relationships with very low density lipoprotein triglyceride and high density lipoprotein2 cholesterol. Arteriosclerosis 5:273-282, 1985
5. Kuusi T, Saarinen P, Nikkila EA: Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2inman. Atherosclerosis 36:589-593, 1980
6. Jackson RL, Yates MT, McNerney CA, Kashyap ML: Relationship between post-heparin plasma lipases, triglycerides and high density lipoproteins in normal subjects. Hormone Metab Res 22:289-294, 1990
7. Cohen JC, Vega GL, Grundy SM: Hepatic lipase: new insights from genetic and metabolic studies. Curr Opin Lipidol 10:259-267, 1999
8. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD: Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 13:147-153, 1993
9. Zambon A, Deeb SS, Bensadoun A, Foster KE, Brunzell JD: In vivo evidence of a role for hepatic lipase in human apoB-containing lipoprotein metabolism, independent of its lipolytic activity. J Lipid Res 41:2094-2099, 2000
10. Hegele RA, Little JA, Vezina C, Maquire GF, Tu L, Wolever TS, Jenkins DJA, Connelly PW: Hepatic lipase deficiency: clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb 13:720-728, 1993
11. Zambon A, Brown BG, Deeb SS, Brunzell JD: Hepatic lipase as a focal point for the development and treatment of coronary artery disease. J Invest Med 49:112-118, 2001
12. Kuusi T, Kesaniemi YA, Vuoristo M, Miettinen TA, Koskenvuo M: Inheritance of high density lipoprotein and lipoprotein lipase and hepatic lipase activity. Arteriosclerosis 7:421-425, 1987
13. Tikkanen MJ, Nikkila EA: Regulation of hepatic lipase and serum lipoproteins by sex steroids. Am Heart J 113:562-567, 1987
14. Baynes C, Henderson AD, Anyaoku V, Richmond W, Hughes CL, Johnston DG, Elkeles RS: The role of insulin sensitivity and hepatic lipase in the dyslipidaemia of type 2 diabetes. Diabet Med 8:560-566, 1991
15. Nie L, Wang J, Clark LT, Tang A, Vega GL, Grundy SM, Cohen JC: Body mass index (BMI) and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity. J Lipid Res 39:1127-1130, 1998
16. Jansen H, Verhoeven AJM, Weeks L, Kastelein JJP, Halley DJ, van de Ouweland A, Jukema JW, Seidell JC, Birkenhager JC: Common C to T substitution at position -480 of the hepatic lipase promotor is associated with a lowered hepatic lipase activity in coronary artery disease patients. Arterioscler Thromb Vasc Biol 17:2837-2842, 1997
17. Guerra R, Wang J, Grundy SM, Cohen JC: A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A 94:4532-4537, 1997
18. Tahvanainen E, Syvanne M, Frick MH, Murtomaki-Repo S, Antikainen M, Kesaniemi YA, Kauma H, Pasternak A Taskinen MR, Ehnholm C: Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study Investigators. J Clin Invest 101:956-960, 1998
19. Hegele RA, Tu L, Connelly PW: Human hepatic lipase mutations and the polymorphisme. Hum Mutat 1:320-324, 1992
20. Brand K, Dugi KA, Brunzell JD, Nevin DN, Santamarina-Fojo S: A novel A-G mutation in intron 1 of the hepatic lipase gene leads to alternative splicing, resulting in enzyme deficiency. J Lipid Res 37:1213-1223, 1996
21. Vega GL, Clark LT, Tang A, Marcovina S, Grundy SM, Cohen JC: Hepatic lipase activity is lower in African American than in white American men: effects of 5′ flanking polymorphism in the hepatic lipase gene. J Lipid Res 39:228-232, 1998
22. Zambon A, Deeb SS, Hokanson JE, Brown BG, Brunzell JD: Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterloscler Thromb Vasc Biol 18:1723-1729, 1998
23. Van 't Hooft FM, Lundahl B, Ragogna F, Karpe F, Olivecrona G, Hamsten A: Functional characterization of 4 polymorphisms in promoter region of hepatic lipase gene. Arterioscler Thromb Vasc Biol 20:1335-1339, 2000
24. Nie L, Niu S, Vega GL, Clark LT, Tang A, Grundy SM, Cohen JC: Three polymorphisms associated with low hepatic lipase activity are common in African Americans. J Lipid Res 39:1900-1903, 1998
25. Tan KCB, Shiu SWM, Chu BYM: Effects of gender, hepatic lipase gene polymorphism and type 2 diabetes mellitus on hepatic lipase activity in Chinese. Atherosclerosis 157:233-239, 2001
26. Kantor MA, Bianchini A, Bernier D, Sady SP, Thompson PD: Androgens reduce HDL2-cholesterol and increase hepatic triglyceride lipase activity. Med Sci Sports Exercise 17:462-465, 1985
27. Botma GJ, Verhoeven AJM, Jansen H: Molecular basis of the association between hepatic lipase activity and obesity, hypertriglyceridemia and insulin-resistance. Circulation 104 (Suppl.):390, 2001
28. Hoogerbrugge N, Jansen H: Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis 146:167-174, 1999
29. Zambon A, Hokanson JE, Brown BG, Brunzell JD: Evidence for a new pathophysiological mevhanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99:1959-1964, 1999
30. Zambon A, Deeb SS, Brown BG, Hokanson JE, Brunzell JD: Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 103:792-798, 2001
31. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275:128-133, 1996
32. Pörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
33. Sachs FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996
34. MRC/BHF Heart Protection: Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 20:725-741, 1999
35. The Diabetes Atorvastatin Lipid Intervention (DALI) study group: The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia - the DALI study: a double-blind randomized placebo controlled trial in patients with type 2 diabetes mellitus and diabetic dyslipidemia. Diabetes Care 24:1335-1341, 2001
36. Friedewald WT, Levy RJ, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 178:499-502, 1972
37. Jansen H. Hop W, van Tol A, Bruschke AV, Birkenhager JC: Hepatic lipase and lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern in human subjects with coronary heart disease. Atherosclerosis 107:45-54, 1994
38. Cai SJ, Wong DM, Chen SM, Chan L: Structure of the human hepatic triglyceride lipase gene. Biochemistry 28:8966-8971, 1989
39. Katzel LI, Coon PJ, Busby MJ, Gotlieb SO, Krauss RM, Goldberg AP: Reduced HDL2 cholesterol subspecies and elevated post-heparin hepatic lipase activity in older man with abdominal obesity and asymptomatic myocardial ischemia. Arterioscler Thromb 12:814-823, 1992
40. Cominacini L, Garbin U, Davoli A, Campagnola M, De Santis A, Pasini, De Santis A, Pasini C, Pastorino AM, Bosello O: High density lipoprotein cholesterol concentrations and postheparin hepatic and lipoprotein lipases in obesity: relationships with plasma insulin levels. Ann Nutr Metab 37:175-184, 1993
41. Carr MC, Hokanson JE, Zambon A, Deeb SS, Barrett PH, Purnell JQ, Brunzell JD: The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. J Clin Endocrinol Metab 86:2831-2837, 2001